Navigation Links
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
Date:6/26/2010

seen in patients with elevated blood sugar levels at baseline (HbA1c greater than or equal to 9.0 percent).(1)
  • The proportion of patients reporting at least one adverse event (AE) was similar for both groups (52.4 percent linagliptin; 58.7 percent placebo).  Hypoglycemia occurred in one patient in each of the groups (0.3 percent linagliptin; 0.6 percent placebo).  Serious AEs were reported in both groups (3.0 percent linagliptin; 4.2 percent placebo) but were not determined by the investigators to be drug related.(1)
  • Patients who received linagliptin as an add-on to metformin with baseline HbA1c greater than or equal to 7.0 percent were more likely to achieve an HbA1c <7.0 percent than those receiving metformin + placebo (26.2 percent versus 9.2 percent, p=0.0001).(2)
    • Linagliptin + metformin showed a statistically significant change in placebo-adjusted postprandial glucose (PPG) levels of -67.1 mg/dl compared to placebo + metformin (p<0.0001).
    • The proportion of patients reporting at least one AE was similar for both groups (52.8 percent linagliptin; 55.4 percent placebo).  Hypoglycemia occurred in five placebo patients (2.8 percent) and three linagliptin patients (0.6 percent), two of which were considered drug-related by the investigator.(2)
  • Patients who received linagliptin as add-on to metformin and sulfonylurea with baseline HbA1c greater than or equal to 7.0 percent were significantly more likely to achieve a target HbA1c  less than or equal to 7.0 percent when treated with linagliptin (29.2 percent) compared to placebo (8.1 percent, p<0.0001).(3)
    • The proportion of patients reporting a severe AE in the linagliptin and placebo groups was 2.4 percent and 1.5 percent
      '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    2. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    3. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    4. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Boehringer Ingelheim Unveils Diabetes Pipeline
    7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    10. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
    11. MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/28/2014)... months endedChange %  30 September 201430 September 2013Turnover 546,011 , ... , 384,242 , 339,113 , 13.3 ... , 49.5 Medical Insurance Administration Service Income , ... Devices and Accessories Sales , 94,580 , 142,683 ... 2,917 , 9,219 , (68.4) Impairment Loss on ...
    (Date:11/26/2014)... Nov. 26, 2014   Royal Philips ... announced expanded availability of its portfolio of ... wDR, MobileDiagnost Opta[i] , ProGrade and PrimaryDiagnost[ii]. With ... available in the U.S., and availability of all ... offers Philips, customers innovative solutions designed to meet ...
    (Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
    Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
    ... at High,Risk , ,WASHINGTON, March 9, 2007 ... history of end-stage renal disease (ESRD), and,these individuals appear ... reports a study in the April Journal of,the American ... disease is more frequent in,African-Americans, who are also at ...
    ... Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused on,infectious ... catheter,treated with a Ceragenin compound demonstrated virtually ... In the study, polyurethane catheters treated with ... along with an,untreated catheter. At day 21, ...
    Cached Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
    (Date:11/28/2014)... The Alternative Health Therapies ... five years. The industry has been buoyed by ... either alternative to conventional Western medicine or complementary ... David Whytcross, “industry revenue has been further boosted ... insurance membership.” Meanwhile, improving economic conditions following the ...
    (Date:11/28/2014)... 27, 2014 (HealthDay News) -- Planning on seconds at ... heartburn -- clinically known as gastroesophageal reflux disease (GERD) -- ... Jordan Josephson, an ear, nose and throat specialist at Lenox ... to help manage GERD on Thanksgiving: Pace ... least two small meals throughout the day. It,s also a ...
    (Date:11/28/2014)... November 28, 2014 An inventor and dental ... on a patient’s filling and it was almost impossible to ... curing light," she said. , The patent-pending Access Light allows ... access to areas of the mouth, as well as avoids ... and safety. Easy to use and clean, it also helps ...
    (Date:11/28/2014)... November 28, 2014 A newly released ... an overview of the influenza virus that will soon be ... , The article begins with a brief explanation of ... symptoms. It reminds families that children under the age of ... from chronic diseases, such as heart and lung diseases, asthma, ...
    (Date:11/28/2014)... November 28, 2014 "Most of my life, ... to use crutches," said an inventor from Findlay, Ohio. "I ... way to support my foot, which inspired me to invent ... offer a convenient way to support an injured foot. The ... It eliminates the need for crutches. The design redistributes weight ...
    Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Don't Let Chronic Heartburn Spoil Your Thanksgiving Feast 2Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
    ... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
    ... , , , VIENNA, ... Industries Ltd. (Nasdaq: TEVA ), today announced results ... corticosteroids (ICSs) in a "real-life" asthmatic population. The study ... to effectively treat both large and small airway inflammation, to ...
    ... , WASHINGTON, Sept. 16 Antidepressant drug ... year, has been known to cause birth defects, but the ... a Philadelphia court has heard. , , ... the drug and urged scientists to conceal Paxil,s risks. The ...
    ... , , BRAINTREE, Mass. and ... HAE ) announced today that it has signed a ... a cooperative of community blood centers. The contract provides ... of innovative blood management software products, including Prelude and Interlude, ...
    ... finds supervised exercise has better results , WEDNESDAY, Sept. ... shockwave treatment for relieving chronic shoulder pain, according to ... to treat shoulder pain, even though a number of ... Norwegian researchers studied 104 men and women, aged 18 ...
    ... , , WASHINGTON, Sept. ... Orthotic and Prosthetic Association today announced that Senators Tom Harkin ... Miller, and Lincoln Diaz-Balart are recipients of their joint organizations, ... view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/aopa/40117/ ...
    Cached Medicine News:Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 2Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 3Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 4Health News:Glaxo Official Memo Urged Scientists to Withhold Information About Paxil's Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage 2Health News:Haemonetics Signs Comprehensive Agreement with Blood Centers of America 2Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 3
    ... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
    ... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
    ... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
    ... Ophthalmics offers the most comprehensive family ... Instruments for Cataract incision, Glaucoma filtration, ... coagulation is achieved with minimal tissue ... Straight eraser styles are available in ...
    Medicine Products: